

Karen A Kurdziel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/448345/publications.pdf>

Version: 2024-02-01

57
papers

2,482
citations

218677

26
h-index

197818

49
g-index

59
all docs

59
docs citations

59
times ranked

3655
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 306-314.	1.9	2
2	Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 324-330.	3.9	13
3	Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study. <i>Lancet Haematology</i> , 2018, 5, e44-e52.	4.6	14
4	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1219-1235.	0.8	30
5	Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 500-508.	6.4	28
6	Novel PET Imaging with Fluorothymidine (FLT) Predicts Relapse Quantitatively at Day 28 Post Transplantation in Patients with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S213-S214.	2.0	2
7	Prospective Study Evaluating Na ¹⁸ F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 886-892.	5.0	78
8	Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. <i>Leukemia and Lymphoma</i> , 2016, 57, 1114-1121.	1.3	23
9	PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. <i>Abdominal Radiology</i> , 2016, 41, 109-118.	2.1	35
10	Longitudinal 18f-FDG-PET-CT Analysis in Newly Diagnosed Multiple Myeloma (NDMM) Patients Following Carfilzomib, Lenalidomide, Dexamethasone Induction and Lenalidomide Maintenance (CRd-R). <i>Blood</i> , 2016, 128, 3274-3274.	1.4	0
11	Novel Imaging Analysis of the Marrow Compartment after Myeloablative HSCT Reveals the Kinetics and Degree of Myeloablation and Cell Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S319-S320.	2.0	0
12	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2015, 1, 746.	7.1	266
13	Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?. <i>Abdominal Imaging</i> , 2015, 40, 3222-3229.	2.0	22
14	Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging. <i>Oncotarget</i> , 2015, 6, 4496-4504.	1.8	38
15	Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. <i>Leukemia</i> , 2014, 28, 413-416.	7.2	24
16	Localized Prostate Cancer Detection with Na ¹⁸ F FACBC PET/CT: Comparison with MR Imaging and Histopathologic Analysis. <i>Radiology</i> , 2014, 270, 849-856.	7.3	141
17	[18F]Fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing $\alpha_5\beta_1$ and $\alpha_5\beta_2$ integrins. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1879-1888.	6.4	43
18	A Pilot Study of the Value of 18F-Fluoro-Deoxy-Thymidine PET/CT in Predicting Viable Lymphoma in Residual 18F-FDG Avid Masses After Completion of Therapy. <i>Clinical Nuclear Medicine</i> , 2014, 39, 874-881.	1.3	19

#	ARTICLE	IF	CITATIONS
19	Imaging in Drug Development. <i>Cancer Drug Discovery and Development</i> , 2014, , 731-746.	0.4	0
20	Assessment of bone metastases in patients (pts) with urothelial carcinoma using 18F-sodium fluoride PET/CT (18F-NaF) versus 18F-fluorodeoxyglucose PET/CT (18F-FDG).. <i>Journal of Clinical Oncology</i> , 2014, 32, 329-329.	1.6	0
21	Focal bone marrow processes and early bone lesions in patients with multiple myeloma (MM) precursor diseases: A prospective study using molecular imaging.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8587-8587.	1.6	0
22	FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT. <i>Blood</i> , 2014, 124, 1147-1147.	1.4	0
23	Functional and molecular imaging of localized and recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 48-59.	6.4	26
24	Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas. <i>Nuclear Medicine and Biology</i> , 2013, 40, 451-457.	0.6	52
25	Meeting the challenges of PET-based molecular imaging in cancer. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 671-680.	3.1	1
26	18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 1487-1493.	7.0	25
27	Reply: Dynamic PET/CT with ¹¹ C-Acetate in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 326.2-327.	5.0	1
28	The Role of PET/CT and SPECT/CT in Oncology Drug Development. <i>Current Molecular Imaging</i> , 2013, 2, 42-52.	0.7	2
29	Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2013, 122, 538-538.	1.4	30
30	11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation. <i>Journal of Nuclear Medicine</i> , 2012, 53, 538-545.	5.0	119
31	The Kinetics and Reproducibility of ¹⁸ F-Sodium Fluoride for Oncology Using Current PET Camera Technology. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1175-1184.	5.0	71
32	Reply: Radiation Exposure Should Not Limit Bone Scintigraphy with 18F-NaF. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1818-1819.	5.0	1
33	Review of functional/anatomical imaging in oncology. <i>Nuclear Medicine Communications</i> , 2012, 33, 349-361.	1.1	148
34	Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies. <i>Drug Resistance Updates</i> , 2012, 15, 50-61.	14.4	190
35	Molecular Imaging in Myeloma Precursor Disease. <i>Seminars in Hematology</i> , 2011, 48, 22-31.	3.4	23
36	Oncologic angiogenesis imaging in the clinic: how and why?. <i>Imaging in Medicine</i> , 2011, 3, 445-457.	0.0	8

#	ARTICLE	IF	CITATIONS
37	Human Dosimetry and Preliminary Tumor Distribution of 18F-Fluoropaclitaxel in Healthy Volunteers and Newly Diagnosed Breast Cancer Patients Using PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1339-1345.	5.0	27
38	IMAGING OF PROSTATE CANCER. , 2011, , 335-373.		1
39	PET Imaging of Multidrug Resistance in Tumors Using 18F-Fluoropaclitaxel. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1792-1798.	2.1	10
40	Imaging Localized Prostate Cancer: Current Approaches and New Developments. <i>American Journal of Roentgenology</i> , 2009, 192, 1471-1480.	2.2	181
41	Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. <i>Journal of Lipid Research</i> , 2009, 50, 1259-1268.	4.2	156
42	New horizons in prostate cancer imaging. <i>European Journal of Radiology</i> , 2009, 70, 212-226.	2.6	66
43	The evolving role of nuclear molecular imaging in cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 829-842.	1.6	23
44	Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. <i>Nuclear Medicine and Biology</i> , 2007, 34, 823-831.	0.6	49
45	Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]Paclitaxel (FPAC). <i>Applied Radiation and Isotopes</i> , 2007, 65, 696-700.	1.5	17
46	Myocardial salvage in patients with non- σ ST-elevation myocardial infarction determined by myocardial perfusion imaging. <i>American Journal of Cardiology</i> , 2005, 95, 398-401.	1.6	6
47	Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 46-53.	6.4	95
48	Pet myocardial glucose metabolism and perfusion imaging: Part I σ Guidelines for patient preparation and data acquisition. <i>Journal of Nuclear Cardiology</i> , 2003, 10, 545-556.	2.1	10
49	Example of imaging solutions to multi-disease biological challenge - imaging of hypoxia. <i>Academic Radiology</i> , 2003, 10, 887-890.	2.5	2
50	American society of nuclear cardiology practice guidelines PET myocardial glucose metabolism and perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2003, 10, 543-556.	2.1	88
51	Using Positron Emission Tomography 2-Deoxy-2-[18F]Fluoro-D-Glucose, 11CO, and 15O-Water for Monitoring Androgen Independent Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2003, 5, 86-93.	2.6	42
52	Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1330-9.	5.0	59
53	Comparison of 2-dimensional echocardiography and myocardial perfusion imaging for diagnosing myocardial infarction in emergency department patients. <i>American Heart Journal</i> , 2002, 143, 659-667.	2.7	37
54	A nonischemic electrocardiogram does not always predict a small myocardial infarction: Results with acute myocardial perfusion imaging. <i>American Heart Journal</i> , 2001, 141, 360-366.	2.7	26

#	ARTICLE	IF	CITATIONS
55	The Panda Sign. Radiology, 2000, 215, 884-885.	7.3	43
56	8:45â€”9:00 Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide. Molecular Imaging and Biology, 2000, 3, 144.	0.3	20
57	"Robo-Rad": An Inexpensive User-Friendly Multimedia Report System for Radiology. Telemedicine and E-Health, 1996, 2, 123-129.	1.3	9